The quest to understand and slow disease progression in multiple sclerosis (MS) continued in 2024, with research revealing ...

导读 2024年欧洲多发性硬化研究和治疗委员会大会（ECTRIMS ...

Fingolimod is associated with a 0.5–0.6% of macular edema, usually presenting within the first 3–4 months; diagnosis usually requires optical coherence tomography and/or fluorescein angiography.

PONVORY rose to the first choice position both in the 200 U.S. neurology study and the 400 multiple sclerosis patients study. The prescribers preferred ponesimod over siponimod, fingolimod and ...

Background: Multiple sclerosis is a chronic inflammatory disease of the central nervous system with a pronounced neurodegenerative component. It has been suggested that novel treatment options are ...

The UK's National Institute for Clinical and Health Excellence has issued final draft guidance recommending the NHS to use Sanofi's Aubagio (teriflunomide) for adult patients with relapsing ...

When it does launch, Zeposia will compete most closely with Novartis’ first-to-market S1P therapy Gilenya (fingolimod) – which made $3.2 billion in 2019 sales – and the Swiss drugmaker’s ...

The prescribers preferred ponesimod over siponimod, fingolimod and ozanimod primarily because of the fewer drug-drug interactions, while the multiple sclerosis patients chose ponesimod because of ...

Medications are the mainstay of treatment for multiple sclerosis (MS). Many of them are used to block the immune system's attack on the nerves and slow or prevent progression and relapses (flare-ups) ...